EntryPoint Capital LLC Trims Stake in Guardant Health, Inc. (NASDAQ:GH)

EntryPoint Capital LLC decreased its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 48.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,337 shares of the company's stock after selling 15,296 shares during the quarter. EntryPoint Capital LLC's holdings in Guardant Health were worth $499,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Prudential Financial Inc. grew its stake in shares of Guardant Health by 2,235.6% in the 4th quarter. Prudential Financial Inc. now owns 229,870 shares of the company's stock valued at $7,023,000 after buying an additional 220,028 shares during the period. Vanguard Group Inc. grew its stake in Guardant Health by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock valued at $368,205,000 after acquiring an additional 350,606 shares during the period. Fox Run Management L.L.C. bought a new stake in shares of Guardant Health during the fourth quarter valued at approximately $369,000. KLP Kapitalforvaltning AS acquired a new position in shares of Guardant Health during the fourth quarter worth approximately $758,000. Finally, Quantbot Technologies LP bought a new position in shares of Guardant Health in the 4th quarter worth $80,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Analyst Ratings Changes

GH has been the subject of a number of recent research reports. Canaccord Genuity Group boosted their price target on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, February 24th. Stifel Nicolaus boosted their target price on shares of Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Raymond James reaffirmed an "outperform" rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Stephens reissued an "overweight" rating and set a $55.00 price objective on shares of Guardant Health in a report on Wednesday. Finally, Guggenheim restated a "buy" rating and issued a $56.00 target price on shares of Guardant Health in a report on Monday, February 24th. Twenty analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of "Buy" and a consensus price target of $48.95.

Remove Ads

Guardant Health Trading Down 4.5 %

GH stock traded down $2.01 during midday trading on Friday, hitting $43.14. The company's stock had a trading volume of 1,168,890 shares, compared to its average volume of 2,167,286. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $50.89. The firm's 50-day moving average is $44.66 and its 200-day moving average is $34.30. The company has a market cap of $5.32 billion, a PE ratio of -12.12 and a beta of 1.50.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to analysts' expectations of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.